Key terms
About MACK
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MACK news
Apr 30
5:32pm ET
Merrimack Pharmaceuticals Announces Nasdaq Delisting and Liquidation Plan
Apr 30
5:17pm ET
Merrimack to voluntary delist common stock on Nasdaq
Mar 27
5:13pm ET
Merrimack’s FDA Approval Milestone and Scheduled Dissolution Vote
Mar 27
4:31pm ET
Merrimack receives $225M milestone payment from Ipsen
Mar 07
4:52pm ET
Merrimack Pharmaceuticals Proposes Liquidation Plan
Feb 16
11:22am ET
Biotech Alert: Searches spiking for these stocks today
Feb 15
11:05am ET
Biotech Alert: Searches spiking for these stocks today
Feb 13
4:34pm ET
Merrimack Pharmaceuticals Weighs Dissolution Post FDA Approval
Feb 13
4:19pm ET
Merrimack reports Ipsen announcement of FDA approval of Onivyde
No recent press releases are available for MACK
MACK Financials
Key terms
Ad Feedback
MACK Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MACK Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range